Targeting gene expression to tumor cells with loss of wild-type p53 function.

abstract：:We previously developed the "immunogene" approach toward cancer gene therapy using epidermal growth factor receptor (EGFR)-mediated endocytosis. Here, we describe an improved immunogene system, in which the antigen-binding (Fab) fragments of the monoclonal antibody (Ab) B4G7 against the human EGFR were conjugated with...

journal_title：Cancer gene therapy

authors： Chen J,Gamou S,Takayanagi A,Ohtake Y,Ohtsubo M,Shimizu N

更新日期：1998-11-01 00:00:00

abstract：:Colon carcinoma accounts for 20% of deaths due to malignancies in the Western world. Once metastases occur, therapeutic options are limited, with an approximate 5-year survival of only 5%. To investigate the potential of new gene therapeutic approaches, a hepatic micrometastasis model of colon carcinoma in BALB/c mice...

journal_title：Cancer gene therapy

authors： Block A,Freund CT,Chen SH,Nguyen KP,Finegold M,Windler E,Woo SL

更新日期：2000-03-01 00:00:00

abstract：:Melanoma incidence is growing at a faster rate than any other human malignancy. Wild-type (wt) p53 is important in both G(1) and G(2) cell cycle arrest, and cyclin D1 (CD1) is necessary for G(1)-->S progression in melanoma cells. We reported that an adenoviral vector containing wt p53 significantly reduced [(3)H]thymi...

journal_title：Cancer gene therapy

authors： Sauter ER,Takemoto R,Litwin S,Herlyn M

更新日期：2002-10-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) have affinity to tumor sites where they home, affecting their biology and growth. Previously, we have isolated mesenchymal cells from the decidua of the human placenta named as decidua-derived MSCs (DMSCs). The aims of the present study were to investigate the migration capacity of DMSCs ...

journal_title：Cancer gene therapy

authors： Vegh I,Grau M,Gracia M,Grande J,de la Torre P,Flores AI

更新日期：2013-01-01 00:00:00

abstract：:Lung cancer is the most frequently occurring cancer in the world and causes more deaths in the United States than does colon, breast, and prostate cancer combined. Despite advances in treatment modalities including radiation, surgery, and chemotherapy, the overall survival in lung cancer remains low. The cytokine tumo...

journal_title：Cancer gene therapy

authors： Sanlioglu S,Luleci G,Thomas KW

更新日期：2001-11-01 00:00:00

abstract：:Developing continuous systemic delivery of endostatin has been a goal of many laboratories. We have employed a method of gene therapy utilizing different viral constructs. Here, we report that a new serotype of adeno-associated viruses, which incorporates canine endostatin, provides dose-dependent transgene expression...

journal_title：Cancer gene therapy

authors： Tjin Tham Sjin RM,Naspinski J,Birsner AE,Li C,Chan R,Lo KM,Gillies S,Zurakowski D,Folkman J,Samulski J,Javaherian K

更新日期：2006-06-01 00:00:00

abstract：:Previous studies have indicated that the cytokine interleukin (IL)-21 may induce both innate and adaptive immune responses against tumors. The goal of this study was to evaluate a new adoptive immunotherapy strategy that combined lymphocytes from mice immunized with a murine myeloma vaccine secreting murine IL-21 (mIL...

journal_title：Cancer gene therapy

authors： Dou J,Wu Y,Wang J,Zhao F,Chu L,Liu C,Wen P,Hu W,Hu K,He XF,Gu N

更新日期：2010-10-01 00:00:00

abstract：:Herpes simplex viruses (HSVs) are important pathogens and ideal for gene therapy due to its large genome size. Previous researches on HSVs were hampered because the technology to construct recombinant HSVs were based on DNA homology-dependent repair (HDR) and plaque assay, which are inefficient, laborious, and time-co...

journal_title：Cancer gene therapy

authors： Wang D,Wang XW,Peng XC,Xiang Y,Song SB,Wang YY,Chen L,Xin VW,Lyu YN,Ji J,Ma ZW,Li CB,Xin HW

更新日期：2018-06-01 00:00:00

abstract：:We aimed to analyze the association between the distribution of dendritic cells (DC) with expression of tumor-infiltrating T lymphocytes and clinicopathologic parameters with prognosis in epithelial ovarian cancer (EOC). Thirty-three EOC patient samples were surgically resected, and pathology was examined for clinicop...

journal_title：Cancer gene therapy

authors： Zhang Z,Huang J,Zhang C,Yang H,Qiu H,Li J,Liu Y,Qin L,Wang L,Hao S,Zhang F,Wang X,Shan B

更新日期：2015-03-01 00:00:00

abstract：:Recurrent or metastatic cancer in most cases remains an incurable disease, and thus alternative treatment strategies, such as oncolytic virotherapy, are of great interest for clinical application. Oncolytic adenoviruses (Ads) have many advantages as virotherapeutic agents and have been safely employed in the clinics. ...

journal_title：Cancer gene therapy

authors： Choi IK,Yun CO

更新日期：2013-02-01 00:00:00

abstract：:We tested three hammerhead ribozymes for their ability to bind and cleave RNA transcripts derived from the E6 and E7 genes of human papillomavirus (HPV) type-18. Targets were located at nucleotides (nt) 123, 309, and 671 of the viral transcript. In vitro each ribozyme hybridized to its target site when the ribozyme:ta...

journal_title：Cancer gene therapy

authors： Chen Z,Kamath P,Zhang S,Weil MM,Shillitoe EJ

更新日期：1995-12-01 00:00:00

abstract：:The herpes simplex virus thymidine kinase gene (HSV-TK) in combination with ganciclovir (GCV), is currently being used in gene therapy-based clinical trials for cancer treatment. Its therapeutic effect is based on a "bystander effect" whereby HSV-TK gene-modified tumor cells are toxic to nearby unmodified tumor cells ...

journal_title：Cancer gene therapy

authors： Ramesh R,Munshi A,Abboud CN,Marrogi AJ,Freeman SM

更新日期：1996-11-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC) recurrence is one of the leading causes of death after orthotopic liver transplantation (OLT). The sixth complement component (C6) is a late-acting complement protein that participates in the assembly of the membrane attack complex, which has an indispensable role in innate and acquired ...

journal_title：Cancer gene therapy

authors： Wang Z,Liao J,Wu S,Li C,Fan J,Peng Z

更新日期：2016-06-01 00:00:00

abstract：:Direct intratumoral injection of a lipid/DNA complex encoding an allogeneic major histocompatibility complex (MHC) class I molecule leads to regression of both an immunogenic murine tumor and also melanoma lesions in some patients. We have sought to understand the mechanism(s) for this augmentation of antitumor activi...

journal_title：Cancer gene therapy

authors： Fox BA,Drury M,Hu HM,Cao Z,Huntzicker EG,Qie W,Urba WJ

更新日期：1998-09-01 00:00:00

abstract：:The clinical potential of tumor therapies must be evaluated using animal models closely resembling human cancers. We investigated the impact of locally delivered interferon-gamma (IFN-gamma) on primary hepatocarcinoma spontaneously developed by T-SV40 transgenic mice. A single intratumor injection of adenovirus IFN-ga...

journal_title：Cancer gene therapy

authors： Baratin M,Ziol M,Romieu R,Kayibanda M,Gouilleux F,Briand P,Leroy P,Haddada H,Rénia L,Viguier M,Guillet JG

更新日期：2001-03-01 00:00:00

abstract：:Angiogenesis is a requirement for solid tumor growth. Therefore, inhibition of this neovascularization is one mechanism by which restoration of wtp53 function may lead to tumor regression. Here we report that adenoviral vector-mediated wild-type p53 transduction results in growth inhibition of squamous cell carcinoma ...

journal_title：Cancer gene therapy

authors： Sherif ZA,Nakai S,Pirollo KF,Rait A,Chang EH

更新日期：2001-10-01 00:00:00

abstract：:Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation of plasma cells. Biomarkers play an important role in evaluating the development and prognosis of MM. Ubiquitin-conjugating enzyme E2T (UBE2T) is served to connect with particular E3 ubiquitin ligase to degraded-relate...

journal_title：Cancer gene therapy

authors： Zhang W,Zhang Y,Yang Z,Liu X,Yang P,Wang J,Hu K,He X,Zhang X,Jing H

更新日期：2019-11-01 00:00:00

abstract：:Drug metabolizing transgene products, which activate bioreductive cytotoxins, can be used to target treatment-resistant hypoxic tumors. The prodrug AQ4N is bioreduced in hypoxic cells by cytochrome P450s (CYPs) to the cytotoxin AQ4. Previously we have shown that intra-tumoral injection of CYP3A4 and CYP2B6 transgenes ...

journal_title：Cancer gene therapy

authors： Yakkundi A,McErlane V,Murray M,McCarthy HO,Ward C,Hughes CM,Patterson LH,Hirst DG,McKeown SR,Robson T

更新日期：2006-06-01 00:00:00

abstract：BACKGROUND:Interferon-gamma (IFN-gamma) gene/retroviral vector cell vaccinations have generated protective responses from unmodified tumor cell challenges as well as a regression of established tumors in animal models. The purpose of this trial was to determine the feasibility and safety of a direct intratumoral inject...

journal_title：Cancer gene therapy

authors： Nemunaitis J,Fong T,Robbins JM,Edelman G,Edwards W,Paulson RS,Bruce J,Ognoskie N,Wynne D,Pike M,Kowal K,Merritt J,Ando D

更新日期：1999-07-01 00:00:00

abstract：:Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tu...

journal_title：Cancer gene therapy

authors： Grandi P,Fernandez J,Szentirmai O,Carter R,Gianni D,Sena-Esteves M,Breakefield XO

更新日期：2010-09-01 00:00:00

abstract：:Chimeric Antigen Receptor (CAR) T-cell therapy, as an approved treatment option for patients with B cell malignancies, demonstrates that genetic modification of autologous immune cells is an effective anti-cancer regimen. Erythropoietin-producing Hepatocellular receptor tyrosine kinase class A2 (EphA2) is a tumour ass...

journal_title：Cancer gene therapy

authors： Hsu K,Middlemiss S,Saletta F,Gottschalk S,McCowage GB,Kramer B

更新日期：2020-09-01 00:00:00

abstract：:Although there are 55 serotypes of adenovirus (Ad) that infect humans, Ad serotype 5 (Ad5) is the most widely studied because of the availability of commercial kits for its genetic manipulation. In fact, engineered Ad 5 is currently being used in all of the 87 global clinical trials utilizing Ad for the treatment of c...

journal_title：Cancer gene therapy

authors： Chen CY,Weaver EA,Khare R,May SM,Barry MA

更新日期：2011-10-01 00:00:00

abstract：:We have described three potential adenovirus type 5 (Ad5)-based replication-competent cancer gene therapy vectors named KD1, KD3, and VRX-007. All three vectors overexpress an Ad5 protein named Adenovirus Death Protein (ADP, also named E3-11.6 K protein). ADP is required for efficient lysis of Ad5-infected cells and s...

journal_title：Cancer gene therapy

authors： Toth K,Tarakanova V,Doronin K,Ward P,Kuppuswamy M,Locke JE,Dawson JE,Kim HJ,Wold WS

更新日期：2003-03-01 00:00:00

abstract：:We have examined the effect of adenoviruses expressing soluble transforming growth factor receptorII-Fc (sTGFβRIIFc) in a 4T1 mouse mammary tumor bone metastasis model using syngeneic BALB/c mice. Infection of 4T1 cells with a non-replicating adenovirus, Ad(E1-).sTβRFc, or with two oncolytic adenoviruses, Ad.sTβRFc an...

journal_title：Cancer gene therapy

authors： Zhang Z,Hu Z,Gupta J,Krimmel JD,Gerseny HM,Berg AF,Robbins JS,Du H,Prabhakar B,Seth P

更新日期：2012-09-01 00:00:00

abstract：:The zinc-fingers and homeoboxes (ZHX) family is a group of nuclear homodimeric transcriptional repressors that interact with a subunit of nuclear factor-Y (NF-YA) and contain two C2H2-type zinc fingers and five homeobox DNA-binding domains. The members of ZHX family form homodimers or heterodimers with other members o...

journal_title：Cancer gene therapy

authors： Liu Y,Ma D,Ji C

更新日期：2015-05-01 00:00:00

abstract：:Oncolytic virotherapy has shown substantial promises as an alternative therapeutic modality for solid tumors in both preclinical studies and clinical trials. The main therapeutic activity of virotherapy derives from the direct lytic effect associated with virus replication and the induction of host immune responses to...

journal_title：Cancer gene therapy

authors： Fu X,Tao L,Rivera A,Xu H,Zhang X

更新日期：2011-11-01 00:00:00

abstract：:Despite the fact that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in cancer cells, TRAIL resistance in cancer cells has challenged the use of TRAIL as a therapeutic agent. First, prostate carcinoma cell lines (DU145, LNCaP and PC3) were screened for sensitivity to a...

journal_title：Cancer gene therapy

authors： Sanlioglu AD,Koksal IT,Karacay B,Baykara M,Luleci G,Sanlioglu S

更新日期：2006-01-01 00:00:00

abstract：:Adenoviral technology has been thoroughly evaluated for delivering genetic material to tumor tissue and the surrounding microenvironment. Almost any gene can be cloned into an adenovirus (Ad) vector, which when combined with strong, constitutively active promoters permit up to a million-fold amplification of the trans...

journal_title：Cancer gene therapy

authors： Card PB,Hogg RT,Gil Del Alcazar CR,Gerard RD

更新日期：2012-07-01 00:00:00

abstract：:Thymidylate synthase (TS) catalyzes de novo production of thymidylate for DNA synthesis and cell proliferation. As such, TS has been a target of antitumor chemotherapy for many years. Our laboratory has identified several antisense oligodeoxynucleotides (ODNs) that downregulate TS mRNA and protein, inhibit cell prolif...

journal_title：Cancer gene therapy

authors： Berg RW,Ferguson PJ,Vincent MD,Koropatnick DJ

更新日期：2003-04-01 00:00:00

abstract：:Lung metastases are a frequent complication of osteosarcoma and a treatment that would reduce the severity of this complication would be of great benefit to patients. We have used a formulation consisting of polyethyleneimine (PEI) and a p53 gene administered in aerosol to treat established lung micrometastases as a m...

journal_title：Cancer gene therapy

authors： Densmore CL,Kleinerman ES,Gautam A,Jia SF,Xu B,Worth LL,Waldrep JC,Fung YK,T'Ang A,Knight V

更新日期：2001-09-01 00:00:00